Mereo BioPharma reports FY2023 revenue $10M, net loss $29.5M; cash $57.4M funds ops into 2026

Mereo BioPharma Group plc

Revenue $10.0M from Ultragenyx milestone and ReproNovo upfront; net loss $29.5M vs $42.2M in 2022.
Cash $57.4M; net cash burn Q4 2023 $6.7M; expected runway into 2026 supporting current plans.
Setrusumab Orbit (Phase 2/3) enrollment completes Q1 2024; Cosmic (Phase 3) H1 2024, by partner Ultragenyx.
Alvelestat Phase 3 plan with partner around end 2024; FDA aligned on SGRQ primary endpoint.
Leflutrozole licensed to ReproNovo for up to $64.25M milestones plus tiered mid-single digit royalties.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mereo BioPharma Group plc reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 27, 2024, Mereo BioPharma Group plc announced its financial results for the year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Mereo BioPharma Group plc filing history →

Source: SEC EDGAR

accession 0001193125-24-078800

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.